Показать сокращенную информацию
dc.contributor.author | Bukach, O. | |
dc.contributor.author | Pronina, A. | |
dc.contributor.author | Dariy, Y. | |
dc.contributor.author | Yarovyk, D. | |
dc.contributor.author | Vachil, P. | |
dc.date.accessioned | 2025-02-21T13:01:32Z | |
dc.date.available | 2025-02-21T13:01:32Z | |
dc.date.issued | 2023 | |
dc.identifier.other | DOI: 10.5281/zenodo.8266139 | |
dc.identifier.uri | http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/26215 | |
dc.description.abstract | Purpose: optimization of rheumatoid arthritis treatment depending on the T-786C polymorphism of the eNOS gene promoter and comorbid pathology. Conclusions. Therefore, after the treatment, a decrease in the level of acute-phase indicators of inflammation was observed in all polymorphic variants of the T-786C eNOS gene, but it was the most significant in carriers of the TT genotype. | uk_UA |
dc.language.iso | en | uk_UA |
dc.publisher | Znanstvena misel journal | uk_UA |
dc.subject | rheumatoid arthritis | uk_UA |
dc.subject | personalized treatment | uk_UA |
dc.subject | eNOS gene promoter T-786C polymorphism | uk_UA |
dc.subject | arterial hypertension | uk_UA |
dc.subject | type 2 diabetes | uk_UA |
dc.subject | abdominal obesity | uk_UA |
dc.title | Personalized treatment of patients with rheumatoid arthritis depending on the T-786С eNOS gene promoter polymorphism and concomitant pathology | uk_UA |
dc.type | Article | uk_UA |